Seven of the nine scFvs utilized showed statistically significant differences in reactivity between the plasma samples from the AD cases compared to the plasma samples from the control cases, including two Aβ variants (C6T and E1), four tau variants (D11C, ADTau2, ADTau4, and ADTau6) and the TDP-43 variant (AD-TDP3) (Figure 1A). The gene discussed is MAPT; the disease is Alzheimer disease.